Bevacizumab in newly diagnosed ovarian cancer
نویسندگان
چکیده
منابع مشابه
Efficacy and Safety of Bevacizumab-Containing Therapy in Newly Diagnosed Ovarian Cancer
OBJECTIVE The aim of this study was to assess the safety and efficacy of extending bevacizumab therapy beyond 15 months in nonprogressive ovarian cancer. PATIENTS AND METHODS In this multinational prospective single-arm study (ClinicalTrials.gov NCT01239732), eligible patients had International Federation of Gynecology and Obstetrics stage IIB to IV or grade 3 stage I to IIA ovarian cancer wi...
متن کاملROLe Of beVacizumab iN NewLy diagNOsed gLiObLastOma
Chemoradiation (CRT) with temozolomide (TMZ/CRT+TMZ) is the standard of care for newly diagnosed glioblastoma (GBM). This phase III trial, conducted by the Radiation Therapy Oncology Group (RTOG), North Central Cancer Treatment Group (NCCTG) and Eastern Cooperative Oncology Group (ECOG), evaluated whether adding bevacizumab (Bev) to standard CRT improves overall survival (OS) or progression-fre...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma
Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with newly diagno...
متن کاملBevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
BACKGROUND Standard therapy for newly diagnosed glioblastoma is radiotherapy plus temozolomide. In this phase 3 study, we evaluated the effect of the addition of bevacizumab to radiotherapy-temozolomide for the treatment of newly diagnosed glioblastoma. METHODS We randomly assigned patients with supratentorial glioblastoma to receive intravenous bevacizumab (10 mg per kilogram of body weight ...
متن کاملA randomized trial of bevacizumab for newly diagnosed glioblastoma.
BACKGROUND Concurrent treatment with temozolomide and radiotherapy followed by maintenance temozolomide is the standard of care for patients with newly diagnosed glioblastoma. Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor A, is currently approved for recurrent glioblastoma. Whether the addition of bevacizumab would improve survival among patients with n...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: The Lancet Oncology
سال: 2015
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(15)00064-9